Background: With the same dose of tacrolimus, lower systemic exposure on the first
| INTRODUCTION
Tacrolimus is well established as an immunosuppressive agent for the prevention and treatment of allograft rejection in solid organ transplantation. Oral tacrolimus is available as an immediate-release formulation that is usually administered twice daily, as well as a prolonged-release formulation for once-daily (morning) dosing.
Interventional studies performed in de novo liver or kidney transplant recipients have shown that these two tacrolimus formulations have a similar efficacy and safety profile. 1, 2 Given that tacrolimus is a medication with a narrow therapeutic window 3, 4 and that systemic exposure is subject to variability between and within patients, 5, 6 tacrolimus therapy is individualized on the basis of systemic exposure in blood by monitoring trough levels as surrogate markers of exposure (area under the curve [AUC]). 5 Previous pharmacokinetic (PK) studies in stable and de novo transplant populations have established that the relationship between trough levels and AUC between the two formulations is similar; obtaining the same trough levels with the two formulations indicated that similar exposure to tacrolimus was obtained. 7, 8 In a phase II study in de novo liver transplant recipients, mean systemic exposure to prolonged-release tacrolimus over a 24-hour period (AUC 0-24 ) on Day 1 post-transplantation was approximately 50%
lower than that for immediate-release tacrolimus at equivalent doses.
Exposure for the two formulations was comparable on Day 14 and at Week 6, although slightly higher doses of prolonged-release tacrolimus were required to achieve parity of exposure. Other than trough levels, there were no PK data for the two formulations between Day 1 and Day 14. 7 To gain a better understanding of the PKs of the two formulations of tacrolimus during the first 2 weeks post-transplant, a study was performed in a subpopulation of patients included in a large, multicenter, phase III, comparative study of the efficacy and safety of immediate-release versus prolonged-release tacrolimus (NCT00189826) in liver transplant recipients. 2 To compensate for the lower systemic exposure observed in the phase II study of prolonged-released tacrolimus, 7 the first dose of the prolongedrelease formulation in this study was doubled compared with that of immediate-release tacrolimus.
| PATIENTS AND METHODS

| Study design
This analysis was a 2-week PK substudy of a multicenter, two- 
| Patients
The study population for the phase III study has been described in detail elsewhere. 2 Briefly, male and female patients (aged ≥18 years) receiving a primary liver, split liver, or whole liver graft, who had received the first dose of tacrolimus within 12 hours (but not later than 24 hours depending on the time of surgery) of skin closure, and who agreed to participate in this PK substudy were included. 
| Study treatment
During this PK substudy, patients were randomized to receive prolonged-release tacrolimus and placebo matching immediaterelease tacrolimus in the morning, and immediate-release tacrolimus placebo in the evening, or immediate-release tacrolimus in the morning and evening, and placebo matching prolonged-release tacrolimus in the morning. All treatments were taken with fluid on an empty stomach, or ≥1 hour before, or 2-3 hours after food. 
| Endpoints
The primary endpoint was the comparison of AUC from 0 to 24 hours (AUC 0-24 ) of tacrolimus. Systemic exposure was also evaluated by using dose-normalized AUC 0-24 (dose-normalized to 0.1 mg/kg). Secondary endpoints were the determination of maximum observed concentration (C max ), time of C max (T max ), and concentration at 24 hours (C 24 )
after the morning tacrolimus dose. Concentration at 12 hours (C 12 )
after the morning dose of immediate-release tacrolimus and AUC from 0 to 12 hours (AUC 0-12 ) was also evaluated. No separate analysis of safety or efficacy was performed for the PK subset.
| Statistical analyses and sample size calculation
Patients in the PK substudy were classified into two sets. The full PK set (FPKS) consisted of all patients enrolled into the PK substudy who signed a PK informed consent form and for whom there were at least some PK assessments. The PK analysis set (PKAS) consisted of all patients from the FPKS for whom all four PK profiles were complete with no missing samples, and for whom there was no major PKrelated protocol violation. Only patients in the PKAS were included in the analysis of PK parameters. A minimum of 12 patients from each treatment group was considered sufficient for the PKAS to characterize the PK parameters.
The PK parameters for prolonged-release and immediate- was assessed for both formulations. Descriptive statistics (mean, standard deviation (SD), median, minimum, and maximum) were calculated for continuous variables; frequency distribution and percentages were summarized for categorical variables.
| RESULTS
| Study population
A total of 35 patients from the phase III study were included in the FPKS; 10 of these patients were excluded from the PKAS for the following reasons: receiving prohibited medication (n=7), questionable dosing (n=2), and pharmacologically implausible blood levels (n=1). Of the 25 patients included in the PKAS, 13 received prolonged-release tacrolimus (mean age 53.4 years) and 12 received immediate-release tacrolimus (mean age 55.7 years). Patient baseline demographics were similar between treatment arms ( Table 1 ). The majority of patients were male, and more men received prolonged-release tacrolimus (n=11; 84.6%) compared with the immediate-release formulation (n=8; 66.7%). All patients in the PKAS were of Caucasian ethnicity.
| Dosage
The first dose of tacrolimus was administered via the nasogastric route in 10 patients in both the prolonged-release tacrolimus and immediaterelease tacrolimus arms (76.9% and 83.3% of patients, respectively).
As per the protocol, the mean daily doses on Day 1 for prolonged- 
| Pharmacokinetic parameters
Reflecting the characteristics of the formulation, median T max for prolonged-release tacrolimus (3-4 hours) occurred later than for immediate-release tacrolimus (1-2 hours) ( Figure 1 ). Mean whole-blood tacrolimus trough levels (C 24 ) for prolonged-release tacrolimus were higher than for immediate-release tacrolimus ( and C 24 is shown in Figure 3 . There was good correlation for both prolonged-release and immediate-release tacrolimus (r=.96 and r=.86, respectively), and the slope of the line of best fit was similar for both formulations.
| DISCUSSION
It has previously been shown in liver transplant recipients that systemic exposure to tacrolimus was approximately 50% lower with prolonged-release tacrolimus compared with immediate-release tacrolimus when administered at equivalent doses. 7 Hence, the present PK study was conducted to assess whether using a higher starting dose for prolonged-release tacrolimus (0.2 mg/kg/day versus 0.1 mg/ kg/day of immediate-release tacrolimus) would compensate for the lower exposure seen with the prolonged-release formulation on Day 1. We also aimed to explore the PKs of tacrolimus during the first 2 weeks post-transplant.
Data from the original 11-03 study showed that initiating therapy at 0.2 mg/kg/day for prolonged-release tacrolimus compared with 0.1 mg/kg/day for immediate-release tacrolimus overcompensated for the lower exposure seen on Day 1 post-transplant in an earlier study (mean (SD) tacrolimus trough levels on Day 7 were 12.0 (5.9) ng/ml versus 9.5 (4.5) ng/mL, respectively). 2 In this PK study, analysis given immediately post-transplant. 9 Initial dosing with prolongedrelease tacrolimus 0.15-0.175 mg/kg/day enabled patients to readily achieve target trough levels of 5-15 ng/mL, which were lower than those achieved with the initial 0.2 mg/kg/day dose. 9 However, it is important to consider that the number of patients in this pharmacokinetics study were far fewer than those in the Phase II study. The present study supports earlier findings in patients with liver transplants that the relationship between C 24 and AUC 0-24 is similar and highly correlated for the two formulations of tacrolimus. 7, 10 Hence, the same whole-blood trough level monitoring concept can be used for both the immediate-release and prolonged-release formulations.
There were a number of limitations to this substudy. Although a total of 12 patients per treatment arm were deemed sufficient for this analysis, the study population was smaller than previous studies of the PKs of tacrolimus. It has previously been shown that tacrolimus bioavailability was significantly higher after partial liver transplant compared with full transplants, and the volume of the split liver should be used to calculate the more appropriate dose of tacrolimus. 11 However, this study did not examine the effects of split liver grafts on the PKs of tacrolimus. Furthermore, most F I G U R E 1 Median T max of prolongedrelease and immediate-release tacrolimus. T max , time of maximum observed concentration; T max is presented as median (range)
patients received their first dose of tacrolimus via the nasogastric route rather than as an oral intact capsule, which may impact tacrolimus absorption and, therefore, the pharmacokinetic profile of tacrolimus on Day 1.
In conclusion, although a higher starting dose of prolongedrelease tacrolimus is required to achieve similar systemic exposure to immediate-release tacrolimus, the data from this study suggest an increment in the range of 50%-100% is adequate to achieve comparable AUC 0-12 , area under the curve from 0 to 12 h; AUC 0-24 , area under the curve from 0 to 24 h; C 12 , concentration at 12 h; C 24 , concentration at 24 h; CI, confidence interval; C max , maximum observed concentration; NA, not analyzed; SD, standard deviation.
F I G U R E 2
Mean AUC 0-24 of prolongedrelease and immediate-release tacrolimus, normalized to a dose of 0.1 mg/kg/d. AUC 0-24 , area under the curve from 0 to 24 h; CI, confidence interval; data presented for ratio of dose-normalized mean AUC 0-24 (90% CI) for prolonged-release tacrolimus versus immediate-release tacrolimus posttransplantation exposure, but this requires further evaluation in a clinical study. This study confirmed that the same therapeutic drug monitoring system that has been established for immediate-release tacrolimus can be used for prolonged-release tacrolimus.
